Compare APT & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | MIRA |
|---|---|---|
| Founded | 1983 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 43.7M |
| IPO Year | 1997 | 2023 |
| Metric | APT | MIRA |
|---|---|---|
| Price | $5.35 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 81.1K | ★ 118.3K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $59,142,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $74.71 | ★ N/A |
| Revenue Growth | ★ 2.25 | N/A |
| 52 Week Low | $4.34 | $0.90 |
| 52 Week High | $7.50 | $2.45 |
| Indicator | APT | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 40.96 |
| Support Level | $4.48 | $0.91 |
| Resistance Level | $5.31 | $1.22 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 15.97 | 0.00 |
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.